Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 8.3x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 02 Jul 2026	US$1.4t	US$169.9b	-US$12,048,878,572.80	16.8x	-117x	8.3x
Sat, 30 May 2026	US$1.3t	US$170.1b	-US$12,180,295,874.92	16.2x	-107.3x	7.7x
Mon, 27 Apr 2026	US$1.3t	US$166.0b	-US$11,982,883,986.99	17.8x	-108.4x	7.8x
Wed, 25 Mar 2026	US$1.3t	US$169.3b	-US$15,116,425,731.11	16.9x	-83.4x	7.4x
Fri, 20 Feb 2026	US$1.3t	US$167.6b	-US$13,402,775,963.67	22x	-100.1x	8x
Sun, 18 Jan 2026	US$1.2t	US$163.5b	-US$15,150,311,707.60	19.7x	-80.8x	7.5x
Tue, 16 Dec 2025	US$1.2t	US$163.7b	-US$15,629,182,813.93	18.8x	-78x	7.4x
Thu, 13 Nov 2025	US$1.2t	US$163.7b	-US$16,361,101,083.00	18.3x	-72.3x	7.2x
Sat, 11 Oct 2025	US$1.2t	US$163.4b	-US$18,215,346,855.44	16.6x	-63.1x	7x
Mon, 08 Sep 2025	US$1.1t	US$163.6b	-US$18,346,659,491.12	15.7x	-58.9x	6.6x
Wed, 06 Aug 2025	US$1.0t	US$159.3b	-US$15,865,734,075.20	16.7x	-65x	6.5x
Fri, 04 Jul 2025	US$960.1b	US$155.8b	-US$23,422,935,456.99	17.3x	-41x	6.2x
Sun, 01 Jun 2025	US$908.1b	US$155.8b	-US$23,980,173,787.04	15.6x	-37.9x	5.8x
Tue, 29 Apr 2025	US$784.0b	US$119.2b	-US$31,078,506,586.14	20.3x	-25.2x	6.6x
Thu, 27 Mar 2025	US$827.3b	US$118.5b	-US$36,884,032,976.26	19.9x	-22.4x	7x
Sat, 22 Feb 2025	US$863.3b	US$117.3b	-US$37,606,528,073.37	17x	-23x	7.4x
Mon, 20 Jan 2025	US$947.4b	US$149.4b	-US$26,286,185,460.05	17.3x	-36x	6.3x
Wed, 18 Dec 2024	US$996.7b	US$149.9b	-US$26,485,748,422.02	16.6x	-37.6x	6.6x
Fri, 15 Nov 2024	US$1.1t	US$150.0b	-US$27,266,729,255.62	17.3x	-39x	7.1x
Sun, 13 Oct 2024	US$902.0b	US$113.1b	-US$36,040,263,614.54	20.6x	-25x	8x
Tue, 10 Sep 2024	US$894.1b	US$113.1b	-US$35,658,177,880.36	22.2x	-25.1x	7.9x
Thu, 08 Aug 2024	US$1.2t	US$166.2b	-US$32,645,503,888.52	23.4x	-35.8x	7x
Sat, 06 Jul 2024	US$1.1t	US$164.5b	-US$28,073,491,589.97	27.9x	-39.9x	6.8x
Mon, 03 Jun 2024	US$1.1t	US$164.6b	-US$26,677,143,877.65	27.4x	-42.1x	6.8x
Wed, 01 May 2024	US$1.1t	US$164.6b	-US$27,373,262,846.23	22.9x	-39.5x	6.6x
Fri, 29 Mar 2024	US$1.2t	US$164.4b	-US$23,753,804,933.92	21.4x	-49.6x	7.2x
Sun, 25 Feb 2024	US$1.2t	US$166.6b	-US$21,694,949,476.21	10.8x	-54.3x	7.1x
Tue, 23 Jan 2024	US$1.4t	US$204.8b	-US$22,505,965,323.00	18.5x	-63.5x	7x
Thu, 21 Dec 2023	US$1.4t	US$204.8b	-US$22,158,313,482.00	18.8x	-61.2x	6.6x
Sat, 18 Nov 2023	US$1.2t	US$204.7b	-US$22,079,363,558.00	18.1x	-54.7x	5.9x
Mon, 16 Oct 2023	US$1.3t	US$207.3b	-US$13,079,327,258.00	16.6x	-96.8x	6.1x
Wed, 13 Sep 2023	US$1.3t	US$207.5b	-US$12,640,460,182.00	17.5x	-101.7x	6.2x
Fri, 11 Aug 2023	US$1.3t	US$207.7b	-US$12,610,114,686.00	17.6x	-101.5x	6.2x
Sun, 09 Jul 2023	US$1.1t	US$186.3b	-US$16,022,507,026.00	12.9x	-69.1x	5.9x


US Market	1.64%
Healthcare	4.13%
Biotech	3.69%
Biotech	3.69%

Company	Last Price	7D	1Y	Valuation
ABBV AbbVie	US$251.06	6.9% +US$28.6b	31.6%	PE123.4x
VRTX Vertex Pharmaceuticals	US$498.01	4.8% +US$5.8b	9.0%	PE29.1x
AMGN Amgen	US$361.33	2.8% +US$5.3b	21.7%	PE25x
MRNA Moderna	US$72.50	20.0% +US$4.8b	139.4%	PS12.9x
RVMD Revolution Medicines	US$187.51	10.4% +US$3.8b	404.2%	PB26.6x

Announcement • Jun 30

Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia

Ascendis Pharma A/S announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA). As previously reported, improvements in annualized growth velocity were maintained and ACH-specific height Z-score increased with TransCon CNP treatment through Week 104. ApproaCH was a randomized, double-blind, placebo-controlled pivotal trial in 84 children with achondroplasia aged 2–11 years, investigating TransCon CNP (100 µg/kg once-weekly) versus placebo for 52 weeks, followed by an open-label extension (OLE) in which all participants received TransCon CNP through Week 104. Radiographic assessments of lower extremity alignment were conducted at baseline, Week 52, and Week 104. Improvements in TFA and TFA Z-scores continued through Week 104 and were greater in children with baseline TFA = 5°. The average TFA in all children treated with TransCon CNP during the double-blind period was 9.1° at baseline, decreasing to 7.7° at Week 52 and 6.9° at Week 104, reflecting a mean absolute change of -2.2 degrees over the two-year treatment period. In the subgroup of children with baseline TFA = 5° (reflecting children with preexisting genu varum), the average TFA was 13.4° at baseline, decreasing to 11.3° at Week 52 and 9.6° at Week 104, reflecting a mean absolute change of -3.8 degrees over the two-year treatment period. The average TFA in children switching from placebo to TransCon CNP treatment at Week 52 was 11.5° at baseline, increasing to 11.8° at Week 52 and decreasing with TransCon CNP treatment to 10.1° at Week 104, reflecting a mean absolute change of -1.7 degrees during the OLE period. In the subgroup of children with baseline TFA = 5°, the average TFA was 18.2° at baseline, increasing to 18.7° at Week 52 and decreasing with treatment to 14.9° at Week 104, reflecting a mean absolute change of -3.8 degrees during the OLE period. In children treated with TransCon CNP in the double-blind period, mean TFA Z-score was 3.62 at baseline and decreased to 3.15 at Week 52 and 2.96 at Week 104, reflecting a mean absolute change of -0.66 over the two-year treatment period. In the subgroup of children with baseline TFA = 5°, mean TFA Z-score was 5.40 at baseline and decreased to 4.67 at Week 52 and 4.36 at Week 104, reflecting a mean absolute change of -1.04 over the two-year treatment period. In children switching from placebo to TransCon CNP at Week 52, mean TFA Z-score was 4.08 at baseline, increased to 4.76 at Week 52, and decreased to 4.28 at Week 104, reflecting a mean absolute change of -0.48 from Week 52 to Week 104. In the subgroup of children with baseline TFA = 5°, mean TFA Z-score was 6.13 at baseline, increased to 7.56 at Week 52, and decreased to 6.35 at Week 104, reflecting a mean absolute change of -1.21 from Week 52 to Week 104. Results also showed that fibula-to-tibia length ratio remained stable in the overall clinical trial population during the open-label extension, reflecting proportional growth of the lower leg. Through up to two years of treatment, TransCon CNP was generally well tolerated, with a low rate of ISRs (all mild), no symptomatic hypotension, and no acceleration of bone age. Most adverse events in TransCon CNP-treated children were mild or moderate, with none leading to treatment discontinuation or withdrawal from the trial. TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration under the trade name YUVIWEL to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

FDA and EU Move to Pull Tavneos After Amgen Q1 Beat and Data Integrity Fallout

Executive VP exercised options and sold US$656k worth of stock

FDA Panel Backs Moderna mRNA Flu Vaccine as Company Expands Cancer and Autoimmune Pipeline

BeOne Medicines Ltd. Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

FDA Approves ZORYVE Cream for Plaque Psoriasis in Children as Young as 2

Evommune Faces Investigation After Executives Sell Ahead of Failed Clinical Trial Announcement

Forecast breakeven date pushed back to 2027

Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia

Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech

AbbVie Inc Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell 2500 Value Benchmark

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index

Secretary & Chief Legal Officer notifies of intention to sell stock

Sephience Launch Drives 75% Rally as PTC Therapeutics Eyes $2 Billion Peak Sales

Aurinia Pharmaceuticals Expands Pipeline With Kezar Life Sciences Acquisition and Zetomipzomib Addition

uniQure to File Huntington’s Gene Therapy BLA in Q3 2026 After FDA Alignment